

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

HOPEWELL PHARMA VENTURES, INC.,  
Petitioner

v.

MERCK SERONO S.A.,  
Patent Owner

---

Case IPR2023-00481  
U.S. Patent No. 8,377,903

---

**PETITIONER HOPEWELL PHARMA VENTURES, INC.’S MOTION FOR  
*PRO HAC VICE* ADMISSION OF JOHN CHRISTOPHER ROZENDAAL  
UNDER 37 C.F.R. § 42.10(c)**

***Mail Stop “PATENT BOARD”***  
Patent Trial and Appeal Board  
U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TABLE OF CONTENTS**

|      |                                                  |   |
|------|--------------------------------------------------|---|
| I.   | INTRODUCTION .....                               | 1 |
| II.  | STATEMENT OF FACTS .....                         | 2 |
| III. | GOOD CAUSE EXISTS FOR THIS MOTION .....          | 4 |
| IV.  | DECLARATION OF INDIVIDUAL SEEKING TO APPEAR..... | 5 |
| V.   | CONCLUSION.....                                  | 6 |

**PETITIONER’S UPDATED EXHIBIT LIST**

| <b><i>Exhibit #</i></b> | <b><i>Description</i></b>                                                                                                                                                       |
|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>1001</b>             | De Luca, G., et al., “Cladribine Regimen for Treating Multiple Sclerosis,” U.S. Patent No. 8,377,903 B2 (filed April 23, 2010; issued February 19, 2013)                        |
| <b>1002</b>             | Declaration of Aaron Miller, M.D.                                                                                                                                               |
| <b>1003</b>             | <i>Curriculum Vitae</i> for Aaron Miller, M.D.                                                                                                                                  |
| <b>1004</b>             | File History for U.S. Patent No. 8,377,903                                                                                                                                      |
| <b>1005</b>             | <i>Intentionally Left Blank</i>                                                                                                                                                 |
| <b>1006</b>             | Noseworthy, J.H., et al., “Multiple Sclerosis,” <i>The New England Journal of Medicine</i> , 343(13):938-952 (2000)                                                             |
| <b>1007</b>             | Neuhaus, O., et al., “Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection,” <i>TRENDS in Pharmaceutical Sciences</i> , 24(3):131-138 (2003)       |
| <b>1008</b>             | Weiner, H.L., et al., “Immunotherapy of Multiple Sclerosis,” <i>Annals of Neurology</i> , 23(3):211-222 (1988)                                                                  |
| <b>1009</b>             | Wingerchuk, D.M., et al., “Biology of Disease, Multiple Sclerosis: Current Pathophysiological Concepts,” <i>Laboratory Investigation</i> , 81(3):263-281 (2001)                 |
| <b>1010</b>             | Kurtzke, J.F., “Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS),” <i>Neurology</i> , 33:1444-1452 (1983)                         |
| <b>1011</b>             | <i>Intentionally Left Blank</i>                                                                                                                                                 |
| <b>1012</b>             | Whitaker, J.N., “Rationale for Immunotherapy in Multiple Sclerosis,” <i>Annals of Neurology</i> , 36:S103-S107 (1994)                                                           |
| <b>1013</b>             | Stelmasiak, Z., et al., “A pilot trial of cladribine (2-chlorodeoxyadenosine) in remitting-relapsing multiple sclerosis,” <i>Medical Science Monitor</i> , 4(1):4-8 (1998)      |
| <b>1014</b>             | Beutler, E., et al., “The treatment of chronic progressive multiple sclerosis with cladribine,” <i>Proceedings of the National Academy of Sciences, USA</i> 93:1716-1720 (1996) |
| <b>1015</b>             | Tortorella, C., et al., “Cladribine Ortho Biotech Inc,” <i>Current Opinion in Investigational Drugs</i> , 2(12):1751-1756 (2001)                                                |
| <b>1016</b>             | Langtry, H.D., et al., “Cladribine, A Review of its Use in Multiple Sclerosis,” <i>BioDrugs</i> , 9(5):419-433 (1998)                                                           |

| <i>Exhibit #</i> | <i>Description</i>                                                                                                                                                                                                        |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>1017</b>      | Rudick, R.A., et al., “Management of Multiple Sclerosis,” <i>The New England Journal of Medicine</i> , 337(22):1604-1611 (1997)                                                                                           |
| <b>1018</b>      | Rice, G.P.A., et al., “Cladribine and progressive MS, Clinical and MRI outcomes of a multicenter controlled trial,” <i>Neurology</i> , 54:1145-1155 (2000)                                                                |
| <b>1019</b>      | Barkhof, R., et al., “Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis,” <i>Neuroradiology</i> , 36:382-387 (1994)                                                            |
| <b>1020</b>      | Pirko, I. and Rodriguez, M., “Pulsed Intravenous Methylprednisolone Therapy in Progressive Multiple Sclerosis: Need for a Controlled Trial,” <i>Archives of Neurology</i> , 61:1148-1149 (2004)                           |
| <b>1021</b>      | Weiner, H.L., et al., “Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment Group,” <i>Neurology</i> , 43:910-918 (1993) |
| <b>1022</b>      | Bodor, N. and Dandiker, Y., “Oral Formulations of Cladribine,” International Publication No. WO 2004/087101 A2 (filed March 26, 2004; published October 14, 2004)                                                         |
| <b>1023</b>      | Grieb, P., et al., “Effect of Repeated Treatments with Cladribine (2-Chlorodeoxyadenosine) on Blood Counts in Multiple Sclerosis Patients,” <i>Archivum Immunologiae Experimentalis</i> , 43:323-327 (1995)               |
| <b>1024</b>      | Schultz, T.W., et al., “Cyclodextrine Cladribine Formulations,” U.S. Patent No. 6,194,395 B1 (filed February 25, 1999; issued February 27, 2001)                                                                          |
| <b>1025</b>      | File History for U.S. Patent No. 7,713,947                                                                                                                                                                                |
| <b>1026</b>      | Beutler, E., “Use of Substituted Adenine Derivatives for Treating Multiple Sclerosis,” U.S. Patent No. 5,506,214 B2 (filed February 18, 1993; issued April 9, 1996)                                                       |
| <b>1027</b>      | Docket Report, <i>Merck KGaA et al. v. Hopewell Pharma Ventures, Inc.</i> , Case No. 1:22-cv-01365-GBW (D.Del.)                                                                                                           |
| <b>1028</b>      | Docket Report, <i>Merck KGaA et al. v. Accord Healthcare, Inc.</i> , Case No. 1:22-cv-00974-GBW (D.Del.)                                                                                                                  |
| <b>1029</b>      | United States District Courts - National Judicial Caseload Profile, June 2022                                                                                                                                             |
| <b>1030</b>      | <i>Curriculum Vitae</i> for Nancy E. Adams, Ed.D.                                                                                                                                                                         |

| <i>Exhibit #</i> | <i>Description</i>                                                                                                                                                                                                        |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>1031</b>      | Romine, J. S., et al., “A Double-Blind, Placebo-Controlled, Randomized Trial of Cladribine in Relapsing-Remitting Multiple Sclerosis,” <i>Proceedings of the Association of American Physicians</i> , 111(1):35-44 (1999) |
| <b>1032</b>      | Docket Report, <i>Merck KGaA et al. v. Aurobindo Pharma USA, Inc., et al.</i> , Case No. 1:23-cv-00039-GBW (D.Del.)                                                                                                       |
| <b>1033</b>      | Bloom, P.M., “Treatment of Multiple Sclerosis with Lymphocyapheresis and Chemo-Immunosuppression,” U.S. Patent No. 4,964,848 (filed June 27, 1988; issued October 23, 1990)                                               |
| <b>1034</b>      | Order Regarding Motion to Stay, <i>Merck KGaA et al. v. Accord Healthcare, Inc. et al.</i> , Case No. 1:22-cv-00974 (D. Del.), December 15, 2022                                                                          |
| <b>1035</b>      | Stipulation and [Proposed] Order Staying Litigation with Respect to Accord Healthcare, Inc., <i>Merck KGaA et al. v. Accord Healthcare, Inc. et al.</i> , Case No. 1:22-cv-00974 (D. Del.), December 14, 2022             |
| <b>1036</b>      | Lassmann, H., et al., “Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy,” <i>TRENDS in Molecular Medicine</i> , 7(3):115-121 (March 2001)                                         |
| <b>1037</b>      | Lublin, F. D., et al., “Defining the clinical course of multiple sclerosis: Results of an international survey,” <i>Neurology</i> , 46:907-911 (1996)                                                                     |
| <b>1038</b>      | Casanova, B., et al., “High clinical inflammatory activity prior to the development of secondary progression: a prospective 5-year follow-up study,” <i>Multiple Sclerosis</i> , 8:59-63 (2002)                           |
| <b>1039</b>      | Publisher's Record for Stelmasiak (EX1013)                                                                                                                                                                                |
| <b>1040</b>      | Declaration of Nancy E. Adams, Ed.D.                                                                                                                                                                                      |
| <b>1041</b>      | <i>Intentionally Left Blank</i>                                                                                                                                                                                           |
| <b>1042</b>      | Shurkovich, S., et al., “Randomized study of antibodies to INF- $\gamma$ and TNF- $\alpha$ in secondary progressive multiple sclerosis,” <i>Multiple Sclerosis</i> , 7:277-84 (2001)                                      |
| <b>1043</b>      | Khoury, S. J., “Multiple Sclerosis: What Have We Learned From Magnetic Resonance Imaging Studies?,” <i>Archives of Internal Medicine</i> , 158:565-73 (1998)                                                              |
| <b>1044</b>      | Roitt, I. M., “Essential Immunology, Sixth Edition,” Blackwell Scientific Publications, 1-29 (1988) (Excerpt)                                                                                                             |

| <b><i>Exhibit #</i></b> | <b><i>Description</i></b>                                                                                                                                                              |
|-------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>1045</b>             | Filippi, M., et al., “The effect of cladribine on T1 'black hole' changes in progressive MS,” <i>Journal of Neurological Sciences</i> , 176:42-44 (2000)                               |
| <b>1046</b>             | Romine, J. S., et al., “Cladribine: Use in Therapy of Multiple Sclerosis,” <i>Biodrugs</i> , 7(5):386-93 (1997)                                                                        |
| <b>1047</b>             | Selby, R., et al., “Safety and Tolerability of Subcutaneous Cladribine Therapy in Progressive Multiple Sclerosis,” <i>Canadian Journal of Neurological Sciences</i> , 25:295-99 (1998) |
| <b>1048</b>             | Liliemark, J., “The Clinical Pharmacokinetics of Cladribine,” <i>Clinical Pharmacokinetics</i> , 32(2):120-31 (1997)                                                                   |
| <b>1049</b>             | <i>Intentionally Left Blank</i>                                                                                                                                                        |
| <b>1050</b>             | <i>Intentionally Left Blank</i>                                                                                                                                                        |
| <b>1051</b>             | U.S. Patent and Trademark Office, Memorandum, Interim Procedure for Discretionary Denials in AIA Post-Grant Proceedings with Parallel District Court Litigation (June 21, 2022)        |
| <b>1052</b>             | Supplemental Declaration of Aaron Miller, M.D. ( <i>served not filed</i> )                                                                                                             |
| <b>1053</b>             | Declaration of Christina E. Dashe in Support of Motion for <i>Pro Hac Vice</i> Admission                                                                                               |
| <b>1054</b>             | Declaration of John Christopher Rozendaal in Support of Motion for <i>Pro Hac Vice</i> Admission                                                                                       |

## I. INTRODUCTION

Pursuant to 37 C.F.R. § 42.10(c) and the Notice of Filing Date Accorded to Petition (Paper 7), Petitioner Hopewell Pharma Ventures, Inc. (“Petitioner”), respectfully requests that the Board recognize John Christopher Rozendaal as counsel *pro hac vice* in this proceeding. Petitioner is not seeking to replace either its current lead or back-up lead counsel with Mr. Rozendaal. Patent Owner does not oppose this motion.

Where the lead counsel is a registered practitioner, a non-registered practitioner may be permitted to appear *pro hac vice* “upon a showing that counsel is an experienced litigating attorney and has established familiarity with the subject matter at issue in the proceeding.” 37 C.F.R. § 42.10(c); *Unified Patents, Inc. v. Parallel Iron, LLC*, Case IPR2013-00639 (P.T.A.B. Oct. 15, 2013) (Paper 7) (setting forth requirements for *pro hac vice* admission).

As set forth in the accompanying Declaration (EX1054), John Christopher Rozendaal is a Director and head of the Trial and Appellate Practice Group at Sterne, Kessler, Goldstein & Fox PLLC and an experienced patent litigation attorney with significant experience representing clients in patent matters before the courts, the Patent Trial and Appeal Board, and U.S. International Trade Commission. Based on the facts detailed below and in his declaration, John Christopher Rozendaal has significant familiarity with the particular subject matter

in this IPR proceeding.

This motion is authorized by the Notice of Filing Date Accorded that was mailed on March 27, 2023. *See* Paper 7, 2.

## II. STATEMENT OF FACTS

As detailed in his declaration, Mr. Rozendaal serves as head of the Trial and Appellate Practice Group at Sterne, Kessler, Goldstein & Fox PLLC, which is the nation's fourth-largest firm specializing in intellectual property matters. He has focused his practice on patent litigation throughout his nearly 25-year-long career as an attorney and has extensive experience representing clients before courts and agencies, including the Board, in patent matters. EX1054, ¶¶8-9. He has been granted *pro hac vice* admission by the Board in post-grant proceedings and interference proceedings (*id.*, ¶9) and has represented clients in numerous appeals involving patents before the U.S. Court of Appeals for the Federal Circuit (*id.*, ¶8).

Mr. Rozendaal has significant knowledge and experience in patent litigation, including through litigating invalidity defenses, defending and deposing witnesses, handling evidentiary issues, and arguing issues of claim construction. *Id.*, ¶¶8-9.

Mr. Rozendaal has been involved in numerous proceedings before the Board, and has worked on such matters since 2019. *Id.*, ¶9. This experience includes: preparing petitions, motions, and other submissions; deposing, defending, and preparing witnesses; and seeking relief from the Board in accordance with

Board procedures. *Id.*

Based on his involvement to date, Mr. Rozendaal has developed an established familiarity with the subject matter of this proceeding, including a close familiarity with the arguments and evidence in the petition. *Id.*, ¶10. He has gained this familiarity through review and analysis of the challenged patent, the prosecution history of the challenged patent, technical literature, the expert declaration, and other sources of information. *Id.*

Mr. Rozendaal has been granted *pro hac vice* admission in post-grant proceedings and interference proceedings, as identified in his declaration. *Id.*, ¶9. Petitioner is concurrently filing a motion for *pro hac vice* admission of Mr. Rozendaal in related proceeding IPR2023-00480.

Mr. Rozendaal is a member in good standing of the bars of District of Columbia since 1999, State of Virginia since 1997, the Supreme Court of the United States (since 2001), and numerous other federal courts of appeal and district courts. *Id.*, ¶2.

Mr. Rozendaal has never been suspended or disbarred from practice before any court or administrative body (*id.*, ¶3), has never been denied admission to practice before any court or administrative body (*id.*, ¶4), and has never received sanctions or contempt citations from any court or administrative body (*id.*, ¶5).

Mr. Rozendaal certifies that he has read and will comply with the Office

Patent Trial Practice Guide and the Board's Rules of Practice for Trials set forth in part 42 of 37 C.F.R. EX1054, ¶6. Mr. Rozendaal certifies that he understands that he will be subject to the Rules of Professional Conduct under 37 C.F.R. §§ 11.101 *et seq.* and disciplinary jurisdiction under 37 C.F.R. § 11.19(a). EX1054, ¶7.

Mr. Rozendaal certifies that in this proceeding he will work in coordination with lead counsel Eldora L. Ellison, who is a registered practitioner. *Id.*, ¶11.

### **III. GOOD CAUSE EXISTS FOR THIS MOTION**

The Board may recognize counsel *pro hac vice* during a proceeding upon a showing of good cause. Based on the facts above, as supported by Mr. Rozendaal's declaration (EX1054), there is good cause to admit Mr. Rozendaal *pro hac vice* in this proceeding given his extensive experience and qualifications (*id.*, ¶¶2, 8-9) and established familiarity with the subject matter at issue in this proceeding (*id.*, ¶10).

In addition, Mr. Rozendaal has significant knowledge and experience in patent litigation, including defending and deposing witnesses, handling evidentiary issues, and arguing issues of claim construction. *Id.*, ¶¶8-9. These skills are readily applicable to post-grant proceedings and favor admitting Mr. Rozendaal to represent Petitioner.

Petitioner will maintain a registered practitioner as lead counsel for at least as long as Mr. Rozendaal is admitted *pro hac vice*. Mr. Rozendaal certifies that he will coordinate and associate with the designated lead counsel for Petitioner,

Eldora L. Ellison, who is a registered practitioner, for the duration of his involvement. *Id.*, ¶11.

#### **IV. DECLARATION OF INDIVIDUAL SEEKING TO APPEAR**

This motion is accompanied by the declaration required by *Unified Patents, Inc. v. Parallel Iron, LLC*, Case IPR2013-00639 (P.T.A.B. Oct. 15, 2013) (Paper 7).

**V. CONCLUSION**

Petitioner submits that there is good cause under 37 C.F.R. § 42.10(c) for the Board to recognize John Christopher Rozendaal as counsel *pro hac vice* during this proceeding.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX PLLC

/Eldora L. Ellison/

Eldora L. Ellison, Ph.D., Esq.  
Registration No. 39,967  
Lead Attorney for Petitioner

Date: January 5, 2024

1101 K Street, NW, 10th Floor  
Washington, DC 20005  
(202) 371-2600

**CERTIFICATE OF SERVICE (37 C.F.R. § 42.6(e))**

I certify that the above-captioned **PETITIONER HOPEWELL PHARMA VENTURES, INC.’S MOTION FOR *PRO HAC VICE* ADMISSION OF JOHN CHRISTOPHER ROZENDAAL UNDER 37 C.F.R. § 42.10(c)** and Exhibit 1054 was served in its entirety on January 5, 2024, upon the following parties via electronic mail:

Emily R. Whelan (Lead Counsel)  
Deric Geng (Back-up Counsel)  
Cindy Kan (Back-up Counsel)  
David B. Bassett (Back-up Counsel)  
Vinita Ferrera (Back-up Counsel)  
WILMER CUTLER PICKERING HALE AND DORR LLP  
[Emily.WheLAN@wilmerhale.com](mailto:Emily.WheLAN@wilmerhale.com)  
[Deric.Geng@wilmerhale.com](mailto:Deric.Geng@wilmerhale.com)  
[Cindy.Kan@wilmerhale.com](mailto:Cindy.Kan@wilmerhale.com)  
[David.Bassett@wilmerhale.com](mailto:David.Bassett@wilmerhale.com)  
[Vinita.Ferrera@wilmerhale.com](mailto:Vinita.Ferrera@wilmerhale.com)  
[WHMerckMavencladIPRs@wilmerhale.com](mailto:WHMerckMavencladIPRs@wilmerhale.com)

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX PLLC  
[/Eldora L. Ellison/](#)

Eldora L. Ellison, Ph.D., Esq.  
Registration No. 39,967  
Lead Attorney for Petitioner

Date: January 5, 2024

1101 K Street, NW, 10th Floor  
Washington, DC 20005  
(202) 371-2600